Orcheston-Findlay Louise, Bax Samuel, Utama Robert, Engel Martin, Govender Dinisha, O'Neill Geraldine
Children's Cancer Research Unit, The Children's Hospital at Westmead, Sydney, NSW 2145, Australia.
Inventia Life Science Pty Ltd., Sydney, NSW 2015, Australia.
Int J Mol Sci. 2021 Mar 15;22(6):2962. doi: 10.3390/ijms22062962.
The life expectancy of patients with high-grade glioma (HGG) has not improved in decades. One of the crucial tools to enable future improvement is advanced models that faithfully recapitulate the tumour microenvironment; they can be used for high-throughput screening that in future may enable accurate personalised drug screens. Currently, advanced models are crucial for identifying and understanding potential new targets, assessing new chemotherapeutic compounds or other treatment modalities. Recently, various methodologies have come into use that have allowed the validation of complex models-namely, spheroids, tumouroids, hydrogel-embedded cultures (matrix-supported) and advanced bioengineered cultures assembled with bioprinting and microfluidics. This review is designed to present the state of advanced models of HGG, whilst focusing as much as is possible on the paediatric form of the disease. The reality remains, however, that paediatric HGG (pHGG) models are years behind those of adult HGG. Our goal is to bring this to light in the hope that pGBM models can be improved upon.
几十年来,高级别胶质瘤(HGG)患者的预期寿命并未得到改善。实现未来改善的关键工具之一是能够忠实地重现肿瘤微环境的先进模型;它们可用于高通量筛选,未来可能实现精确的个性化药物筛选。目前,先进模型对于识别和理解潜在的新靶点、评估新的化疗化合物或其他治疗方式至关重要。最近,各种方法已开始应用,这些方法使得复杂模型(即球体、类肿瘤、水凝胶包埋培养物(基质支持)以及通过生物打印和微流控技术组装的先进生物工程培养物)得以验证。本综述旨在介绍HGG先进模型的现状,同时尽可能聚焦于该疾病的儿科形式。然而,现实情况仍然是,儿科HGG(pHGG)模型比成人HGG模型落后数年。我们的目标是揭示这一点,希望能改进小儿胶质母细胞瘤(pGBM)模型。